Kiadis Pharma announces maiden Financial Results for the six months ended 30 June 2015
Kiadis Pharma N.V. (“Kiadis Pharma” or “Company”) (Euronext Amsterdam and Brussels: KDS), a recently-listed clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces its maiden unaudited financial results for the six months ended 30 June 2015, which have been prepared in accordance with the IAS 34 “Interim Financial Reporting” as adopted by the European Union.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150824005842/en/
Continued good progress made in developing lead product ATIR101™ for
- Full enrolment of the ongoing Phase II clinical study has been accomplished;
- Readout of the primary endpoint results of this study is still expected in Q1 2016;
- Establishing a closed manufacturing process that allows for automation is advancing according to plan.
- Preparations underway to run another study, testing repeat dose administration of ATIR101™ in parallel with the ongoing Phase II trial.
- ATIR101™ granted an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data by the European Medicinal Agency (EMA).
- The Company further strengthened its Supervisory Board with the appointment of Dr. Vincent Brichard as an independent member.
- Kiadis Pharma N.V. listed its shares with an initial public offering (IPO) on Euronext Amsterdam and Brussels on 2 July 2015. IPO proceeds (€34.7 million gross) did not contribute to the equity and cash position for the first six months ended 30 June 2015 and hence are not included in these financial results.
|Total revenue and other income||-||-||-|
|Research and development||(4.7)||(2.2)||(2.5)|
|General and administrative||(7.0)||(0.7)||(6.3)|
|Net financial result||2.2||(0.6)||2.8|
|Net operational cash flow||(3.6)||(2.7)||(0.9)|
|Cash at end of period||2.5||3.6||(1.1)|
A full financial report for the six months ended 30 June 2015 is available on Kiadis Pharma’s website.
Commenting on the maiden financial results, Manfred Rüdiger, CEO of Kiadis Pharma, said: “We are pleased to be making continued good progress with our Phase II clinical trial using ATIR101™ and that we remain on track. Having completed our recent IPO we are now completely driven to create life-saving treatments for patients with blood cancers and inherited blood disorders and to create value for our shareholders.”
During an allogeneic hematopoietic stem cell transplantation (HSCT) treatment, the bone marrow, harbouring the diseased cells, is completely destroyed and subsequently replaced by stem cells from a healthy donor. After an HSCT treatment it usually takes at least six to twelve months to recover to near-normal blood cell levels and immune cell functions in a patient that has received a transplant. During this period, the patient is highly susceptible and vulnerable to infections caused by bacteria, viruses and fungi. Immune cells in ATIR™ (Allodepleted T-cell ImmunotheRapeutics) will help fight these opportunistic infections and bridge the time until the immune system has fully re-grown from stem cells in the transplanted graft.
In ATIR™, T-cells that cause Graft-versus-Host-Disease (GVHD) are eliminated from the donor lymphocytes, which minimises the risk of GVHD and any related morbidity and mortality. At the same time, ATIR™ contains potential cancer killing T-cells from the donor that could eliminate residual cancer cells and avoid the return of the disease. ATIR™ allows the use of haploidentical grafts that are almost entirely depleted of T-cells, which eliminates the need for immunosuppressive drugs. ATIR™ subsequently provides the patient with immune cells that do not cause GVHD. As a result, ATIR™ solves the problem of not finding a matched donor in time and has the potential to make curative HSCT a viable option to many more patients.
The Company estimates that approximately 35% of patients who are eligible for, and who are in urgent need of, HSCT will not find a matching donor in time. A partially matched (haploidentical) family donor, however, will be available to over 95% of patients. The use of haploidentical donor grafts without ATIR™ is only feasible in conjunction with severe immunosuppression which renders the patient highly vulnerable to infections with severe clinical complications, resulting potentially in death.
About Kiadis Pharma
Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The Company believes that its innovative products have the potential to address the current risks and limitations connected with allogeneic hematopoietic stem cell transplantation (HSCT). Although currently not a viable option for many patients, HSCT is generally regarded as the most effective curative approach to blood cancers and certain inherited blood disorders. The Company expects that HSCT could become a first-choice treatment for blood cancers and inherited blood disorders once current risks and limitations are addressed, thereby meeting a significant unmet medical need with its products.
Currently, ATIR™101 is being tested in an open-label Phase II trial in patients with blood cancer who have not found a matching donor and where a partially matched (haploidentical) family member is used as donor for HSCT.
Kiadis Pharma is based in Amsterdam, the Netherlands and its shares are listed on Euronext Amsterdam and Euronext Brussels. Further information can be found at: www.kiadis.com
This press release contains regulated information (gereglementeerde informatie) within the meaning of the Dutch Financial Supervision Act (Wet op het financieel toezicht) which must be made publicly available pursuant to Dutch law. This press release is intended for information purposes only.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Manfred Ruediger, CEO
Tel. +31 20 314 02 50
Consilium Strategic Communications
Mary-Jane Elliott, Lindsey Neville, Hendrik Thys
Tel: +44 (0) 203 709 5708
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ThreatMetrix Exceeds 45% Annual Growth as Organizations Embrace Digital Identity as Must-Have Technology18.12.2017 13:00 | Pressemelding
ThreatMetrix ®, The Digital Identity Company®, today announced 45 percent growth in billings year-on-year, as implementing digital identity solutions became a key priority for organizations in 2017. In the past quarter, average daily transaction volume processed by ThreatMetrix surged from 75 million to more than 100 million transactions, contributing rich data to the world’s only digital identity graph. Throughout 2017, nearly 150 new companies per quarter were added to the Digital Identity Network®, giving ThreatMetrix customers an unparalleled global view into true digital identity and user trust. “Organizations of all shapes and sizes are embracing ThreatMetrix ID™ to recognize true customers, operate digital businesses securely and profitably, and improve the user experience – all without compromising privacy,” says Frank Teruel, chief finance off
DWC Secures € 10,8 M From GEM Global18.12.2017 10:54 | Pressemelding
Diversified World Corporation 3.0 spa, (“DWC 3.0” or “the Company“) is a listed company at Euronext Access Market in Paris, Symbol (MLDWC:FP). Today, DWC 3.0 is pleased to announce that it has signed a contract for a € 10, 8 million funding facility under a three years warrants agreement, (the “Agreement”) with GEM Global Yield Fund, the private alternative investment group. These € 10,8 million will be raised by issuing 30 million warrants that can be exercised within three years by GEM Global Yield Fund, at the price which represents the nominal value of the share. The Company will sign within a very short time an agreement with a specialist sponsor in order to upgrade its listing to GROWTH Euronext Market in Paris. About DWC 3.0 The Company considers important its presence within the Fine Art sector since Merrill Lynch -Cap Gem
EURid Hosts Green Discussion Panel at The 2017 Internet Governance Forum in Geneva18.12.2017 10:00 | Pressemelding
EURid understands the importance that possessing a neutral carbon footprint has on the planet, which is why it has, and continues to support sustainable projects all over the world. Since May 2012, EURid has been Eco-Management and Audit Scheme (EMAS) certified, which reflects its continuous pursuit towards being a sustainable organisation. As part of its EMAS certification, EURid has issued and instituted an environmental policy, through which it has achieved the following goals: In 2015, EURid joined forces with the environmental Spanish non-profit organisation FAPAS. A number of fruit trees were planted in Asturias, Spain, an area populated by the endangered European brown bear. EURid also purchased verified CO2 credits to contribute to the Ecomapuà project with the goal of conserving the rich biodiversity in the Amazon.
BearingPoint Achieves Platinum Status in the Salesforce Consulting Partner Program18.12.2017 09:00 | Pressemelding
Management and technology consultancy BearingPoint is officially designated a Salesforce Platinum Consulting Partner. The prestigious Platinum Consulting Partner status marks an important milestone for the consultancy and demonstrates its commitment to help the world's most innovative brands enhance their customer experience and run their business in the cloud by leveraging the power of the Salesforce platform. With many new engagements this year, BearingPoint has also been able to significantly increase the number of Salesforce certifications while delivering great value to clients by integrating the Salesforce platform into their business. “Reaching the Platinum Consulting Partner status within less than 3 years basically coming from zero has been a huge feat and shows the focus, dedication, and energy of our fast-growing Salesforce community at BearingPoint,” says Markus
Timor Telecom Enhances International Voice Connections in Timor-Leste Through SES Networks18.12.2017 07:55 | Pressemelding
Timor Telecom (TT), the largest telecommunications operator in Timor-Leste, has expanded its partnership with SES Networks to enable international voice traffic between Timor-Leste and the rest of the world, SES announced today. Under the new agreement, TT will contract capacity on the high-powered NSS-12 geostationary earth orbit (GEO) satellite to establish a point-to-point link connecting Dili, Timor with Sintra, Portugal. Today, residents of Timor-Leste benefit from high speed 4G/LTE mobile data and broadband services provided by TT, which are powered by SES’s O3b medium earth orbit (MEO) satellite network. With its capacity uptake on NSS-12, TT will broaden its suite of services with the carriage of international voice traffic between Timor-Leste and the rest of the world. This enables TT to continue empowering local communities with superior services and to meet all th
Steeper Energy Announces EUR 50.6 M (DKK 377 M) Advanced Biofuel Project with Norwegian-Swedish joint venture Silva Green Fuel in Licensing Deal18.12.2017 07:00 | Pressemelding
Steeper Energy, a Danish-Canadian clean-fuel company, is partnering with Silva Green Fuel, a Norwegian-Swedish joint venture, to construct a EUR 50.6 M (DKK 377M) industrial scale demonstration plant at a former pulp mill located in Tofte, Norway leading to a future commercial scale project. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171217005029/en/ Steeper will license its proprietary Hydrofaction™ technology to Silva, who will build the facility over the next 18 months. The demonstration plant will use woody residues as feedstock that are converted to renewable crude oil and, in turn, will be upgraded to renewable diesel, jet or marine fuel. Steeper’s Hydrofaction™ technology was selected by Silva after an exhaustive due diligence review of some 40 other technologies. Hydrofaction™ harnesses water
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom